Pressmeddelande -
Affibody Licenses Albumod™ Half-life Extension Technology to MedImmune
Solna, Sweden, December 24, 2015. Affibody AB today announced that MedImmune has extended its Albumod™ platform licensing agreement
Affibody AB has signed a continuation of a license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for the use of Affibody’s proprietary Albumod™ platform.
The Albumod™ platform extends the circulatory half-life of biopharmaceuticals, which helps prolong the time a molecule works in the body. This could lead to superior pharmacokinetics and increased patient compliance.
The albumin-binding technology will be applied to an undisclosed number of Medimmune’s proprietary compounds. Affibody will receive milestone payments, as well as royalties on any resulting sales from licensing the Albumod™ platform. Further details of the agreement have not been disclosed.
- MedImmune’s desire to continue the collaboration further validates that our Albumod™ technology can play a key role in the accelerated development of new drug candidates with improved properties, says David Bejker, CEO of Affibody.
Ämnen
- Hälsa, sjukvård, läkemedel
Kategorier
- collaboration agreement
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing. Affibody has ongoing commercial relationships with several companies including Abclon, Biotest, Daewoong, Daiichi Sankyo, GE, MedImmune, Nordic Nanovector, and Swedish Orphan Biovitrum.
Further information can be found at: www.affibody.com
